-+ 0.00%
-+ 0.00%
-+ 0.00%

Lucid Diagnostics study shows 95% cell collection success with EsoCheck in 11,991 patients

PUBT·11/03/2026 13:15:54
Listen to the news
Lucid Diagnostics study shows 95% cell collection success with EsoCheck in 11,991 patients
  • Lucid Diagnostics announced published real-world study results for its EsoGuard esophageal precancer test in the peer-reviewed journal Diagnostics.
  • The study covered 11,991 at-risk patients tested from January 2023 through June 2024.
  • EsoCheck cell collection was rapid and well tolerated across operators, including newly trained personnel; no device-related adverse events were reported.
  • The findings support broader clinical deployment as the company accelerates commercialization, with EsoGuard now fully reimbursed by Medicare nationwide.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lucid Diagnostics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611030815PR_NEWS_USPR_____NY87684) on November 03, 2026, and is solely responsible for the information contained therein.